Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
District of Massachusetts Rejects Per Se AKS Liability for Commissioned, Independent Contractor Sales Representatives But Allows FCA Claims to ProceedOctober 26, 2026DOJ Launches Criminal and Civil Self-Disclosure Programs Relevant to Healthcare and Life Sciences CompaniesOctober 26, 2026DOJ and HHS Launch Healthcare FCA Self-Disclosure Pilot Program with Fixed Repayment MultiplierOctober 22, 2026HHS Secretary Extends HHS-OIG Exclusion Authority to CMS, Expanding the Administration's Anti-Fraud CampaignOctober 19, 2026DOJ Fraud Division and HHS-OIG Announce Joint Self-Disclosure Policy, Directing Healthcare Companies to Bring Potential Criminal Matters to DOJ FirstOctober 16, 2026Court Grants Summary Judgment in Kickback-Based FCA Case, Holding Relator Failed to Prove Remuneration or WillfulnessOctober 7, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory